Lenalidomide Plus R-ESHAP Feasible for Relapsed, Refractory Lymphoma

Share this content:
Lenalidomide in combination with R-ESHAP is feasible and demonstrated encouraging outcomes in diffuse large B-cell lymphoma.
Lenalidomide in combination with R-ESHAP is feasible and demonstrated encouraging outcomes in diffuse large B-cell lymphoma.

Lenalidomide in combination with R-ESHAP (rituximab, etoposide, cisplatin, cytarabine, methylprednisolone) is feasible and demonstrated encouraging outcomes in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a study published in the British Journal of Haematology has shown.1

Because patients with DLBCL who fail rituximab-containing therapy have a poor outcome with the current salvage regimens, researchers sought to evaluate the feasibility, efficacy, and tolerability of lenalidomide plus R-ESHAP in a phase 1b study.

For the study, researchers enrolled 19 patients with relapsed or refractory DLBCL. Participants received lenalidomide at escalating doses on days 1 to 14 of every 21-day cycle for 3 cycles, in combination with R-ESHAP. Patients who responded then received treatment with BEAM (carmustine, etoposide, cytarabine, melphalan) followed by autologous hematopoietic cell transplantation.

Lenalidomide at a dose of 10 mg per day was identified as the maximum tolerated dose after 1 patient who received 15 mg daily experienced dose-limited grade 3 angioedema and 2 patients experienced mobilization failure.

RELATED: Blinatumomab Monotherapy Seems Effective for DLBCL

Results showed that all toxicities associated with the first regimen resolved and no grade 4 or 5 non-hematologic toxicities were reported.

In terms of efficacy, the complete remission rate was 47.4% and the overall response rate was 78.9%. Researchers found that the 2-year progression-free survival and 2-year overall survival rate was 44% and 63%, respectively, after a median of 24.6 months of follow-up.

Reference

  1. Martin A, Redondo AM, Dlouhy I, et al. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group [published online ahead of print February 5, 2016]. Brit J Haematol. doi: 10.1111/bjh.13945.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters